Pharmaceutical

AbbVie and Neomorph link on oncology/immunology glue degraders

AbbVie and Neomorph are set to enter a partnership and option-to-license agreement to develop molecular glue degraders.

Jan 24, 2025 - 06:00
AbbVie and Neomorph link on oncology/immunology glue degraders
AbbVie and Neomorph are set to enter a partnership and option-to-license agreement to develop molecular glue degraders.
Read the original article

Tags:

Previous Article

Emcure Pharmaceuticals opens new R&D centre in Gujarat, India

Next Article

Pharmaceutical Technology Excellence Awards 2024 – Winners Announced!

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Does Moderna’s RSV vaccine lose efficacy faster than others?

Does Moderna’s RSV vaccine lose efficacy faster than ot...

Feb 9, 2024

Generics expected to improve access for patients with idiopathic pulmonary fibrosis

Generics expected to improve access for patients with i...

Sep 27, 2023

Amneal’s CREXONT gains FDA approval for Parkinson’s treatment

Amneal’s CREXONT gains FDA approval for Parkinson’s tre...

Aug 9, 2024